Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MDM4 | O15151 | 3/20 | 0.54 |
| ▸ | TP53 | P04637 | 3/20 | 0.54 |
| ▸ | CASP3 | P42574 | 2/20 | 0.49 |
| ▸ | TLR2 | O60603 | 4/20 | 0.49 |
| ▸ | MDM2 | Q00987 | 4/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | CTSL | P07711 | 1/20 | 0.46 |
| ▸ | CTSB | P07858 | 1/20 | 0.46 |
| ▸ | CTSS | P25774 | 1/20 | 0.46 |
| ▸ | CTSK | P43235 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL119686 | 1.00 | MDM4 (0.54) | MDM4TP53CASP3TLR2MDM2 | |
| SCHEMBL29400667 | 1.00 | MDM4 (0.54) | MDM4TP53CASP3TLR2MDM2 | |
| SCHEMBL30062876 | 1.00 | MDM4 (0.54) | MDM4TP53CASP3TLR2MDM2 | |
| SCHEMBL178739 | 1.00 | MDM4 (0.54) | MDM4TP53CASP3TLR2MDM2 | |
| SCHEMBL118173 | 1.00 | MDM4 (0.54) | MDM4TP53CASP3TLR2MDM2 | |
| SCHEMBL23722984 | 0.99 | MDM4 (0.55) | MDM4TP53CASP3TLR2MDM2 | |
| SCHEMBL119459 | 0.99 | MDM4 (0.55) | MDM4TP53CASP3TLR2MDM2 | |
| SCHEMBL119456 | 0.99 | MDM4 (0.55) | MDM4TP53CASP3TLR2MDM2 | |
| SCHEMBL29709621 | 0.99 | MDM4 (0.55) | MDM4TP53CASP3TLR2MDM2 | |
| SCHEMBL31437097 | 0.97 | MDM4 (0.55) | MDM4TP53CASP3TLR2MDM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 90 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4748847-A1 | PEPTIDE COMPLEX HAVING VEGFR -2 AGONIST ACTIVITY | Peptidream Inc (JP) | 2026-05-27 | — | — | EP | disclosed |
| US-20260139257-A1 | PLIN1 RNAi INTERFERENCE AGENTS | ELI LILLY AND CO (US) | 2026-05-21 | — | — | US | disclosed |
| US-20260124313-A1 | SITE-SPECIFIC COVALENT LIGATION OF HUMAN SERUM ALBUMIN | UNIV CALIFORNIA (US) | 2026-05-07 | — | — | US | disclosed |
| EP-4732286-A2 | COMPOSITIONS AND METHODS FOR ENCRYPTING, STORING, AND DECRYPTING INFORMATION IN OLIGOMERS | Board of Regents, The University of Texas System (US) | 2026-04-29 | — | — | EP | disclosed |
| US-20260070945-A1 | MACROCYCLIC IMMUNOMODULATORS | BRISTOL-MYERS SQUIBB COMPANY | 2026-03-12 | — | — | US | disclosed |
| US-20260049101-A1 | TOPICAL TREATMENT OF SKIN CANCER USING OLIGOPEPTIDES | BACOBA AG (CH) | 2026-02-19 | — | — | US | disclosed |
| EP-4695268-A1 | ANTIBACTERIAL COVALENT PEPTIDE INHIBITORS | Université de Bordeaux (FR) | 2026-02-18 | — | — | EP | disclosed |
| US-20260022142-A1 | MACROCYCLIC IMMUNOMODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2026-01-22 | — | — | US | disclosed |
| US-20260001914-A1 | MACROCYCLIC PEPTIDES TARGETING KRAS | MERCK SHARP & DOHME LLC (US) | 2026-01-01 | — | — | US | disclosed |
| US-20260001924-A1 | NEMO COILED COIL MIMICS AND METHODS OF USING SAME | NEW YORK UNIVERSITY (US) | 2026-01-01 | — | — | US | disclosed |
| WO-2022215745-A1 | SUBSTANCE OF NOVEL SIDEROPHORE-TYPE ANTIFUNGAL AGENT (COMPOUND) AND USE OF SAME | 国立研究開発法人理化学研究所 | 2022-10-13 | — | — | WO | disclosed |
| EP-4069684-A2 | COMPOUNDS AND METHODS FOR AMINE OXIDASE IMAGING | ETH Zurich (CH) | 2022-10-12 | — | — | EP | disclosed |
| WO-2022202816-A1 | PEPTIDE AND PEPTIDE-CONTAINING COMPOSITION | ペプチエイド株式会社 | 2022-09-29 | — | — | WO | disclosed |
| US-20220289802-A1 | NEMO COILED COIL MIMICS AND METHODS OF USING SAME | CORNELL UNIVERSITY | 2022-09-15 | — | — | US | disclosed |
| US-11440938-B2 | Stabilized minimal coiled-coil mimetics | NEW YORK UNIVERSITY (US) | 2022-09-13 | — | — | US | disclosed |
| US-20220283131-A1 | COMPOSITION FOR DETECTING OR MEASURING ANALYTES | BERTIS CO., LTD. (KR) | 2022-09-08 | — | — | US | disclosed |
| EP-4043478-A1 | CYCLIC PEPTIDE COMPOUND HAVING KRAS INHIBITING ACTION | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2022-08-17 | — | — | EP | disclosed |
| EP-3974563-A1 | CYCLIC PEPTIDES | Chugai Seiyaku Kabushiki Kaisha (JP) | 2022-03-30 | — | — | EP | disclosed |
| US-11279734-B2 | Solution-phase affinity selection of inhibitors from combinatorial peptide libraries | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2022-03-22 | — | — | US | disclosed |
| WO-2022050529-A1 | COMPOSITION FOR DETECTING OR MEASURING ANALYTE | ㈜베르티스 | 2022-03-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11440938-B2 | Stabilized minimal coiled-coil mimetics | COIL, CALCOCO2, SMC2 | MDM4 256/4885TP53 657/4885CASP3 3879/4885 |
| US-20260022142-A1 | MACROCYCLIC IMMUNOMODULATORS | CD274, PDCD1LG2, PDCD1 | MDM4 3040/4885TP53 421/4885CASP3 1560/4885 |
| US-11279734-B2 | Solution-phase affinity selection of inhibitors from combinatorial peptide libraries | TP53, MDM2, MDM4 | MDM4 3/4885TP53 1/4885CASP3 2615/4885 |
| US-20260070945-A1 | MACROCYCLIC IMMUNOMODULATORS | CD274, PDCD1, PDCD1LG2 | MDM4 2686/4885TP53 428/4885CASP3 1567/4885 |
| US-20260124313-A1 | SITE-SPECIFIC COVALENT LIGATION OF HUMAN SERUM ALBUMIN | GLP1R, ALB, GIPR | MDM4 4874/4885TP53 2182/4885CASP3 1790/4885 |
| US-20260139257-A1 | PLIN1 RNAi INTERFERENCE AGENTS | PLIN1, PLIN3, PLIN5 | MDM4 3255/4885TP53 4176/4885CASP3 2810/4885 |
| US-20260001924-A1 | NEMO COILED COIL MIMICS AND METHODS OF USING SAME | DDX21, PHAX, RBX1 | MDM4 2407/4885TP53 2772/4885CASP3 3274/4885 |
| US-20220289802-A1 | NEMO COILED COIL MIMICS AND METHODS OF USING SAME | COIL, CALCOCO2, NCAPH | MDM4 2743/4885TP53 3446/4885CASP3 3773/4885 |
| US-20260001914-A1 | MACROCYCLIC PEPTIDES TARGETING KRAS | KRAS, NRAS, HRAS | MDM4 1577/4885TP53 11/4885CASP3 2464/4885 |
| US-20260049101-A1 | TOPICAL TREATMENT OF SKIN CANCER USING OLIGOPEPTIDES | NGLY1, MC1R, EGFR | MDM4 2280/4885TP53 190/4885CASP3 1188/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.